#oral-anti-obesity-drug

#oral-anti-obesity-drug

Gould's findings were consistent with previous conjectures, where the apparent lower lung function of Black people was part of a justification for enslavement.

We've created a small molecule chemical which gets in your body very well. It can mimic the effects of the peptide and can be taken more conveniently any time of day without any food or water restrictions.

The INLIGHT interim readout reported a 14.3% placebo-adjusted reduction in visceral fat six months after a single dose, alongside preservation of lean muscle mass - a differentiated profile compared to GLP-1 therapies that often reduce muscle alongside fat.

The global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) has surged to 1.3 billion people, marking a 143% increase over the past three decades. By 2050, projections indicate that this number could rise to 1.8 billion, primarily due to rising obesity and blood sugar levels.

Lilly's fourth quarter revenue reached $19.29 billion, up 42.6% year-over-year, powered almost entirely by two products. Mounjaro generated $7.41 billion, up 110%, while Zepbound added $4.26 billion, up 123%.

Emma Dyer remembers the moment she clicked "buy now" on a set of weightloss jabs she found online. She had no medical consultation, no ID checks, and no questions about her history of anorexia and bulimia. "It was just so easy - too easy," she says. "They never asked for my medical history or what medication I was taking. It was like buying groceries."

The weight loss jabs Ozempic, Mounjaro and Wegovy - a type of medicine containing semaglutide - are increasingly being seen as a medical wonder of the age. They bring great benefits to people with diabetes and obesity.

New research, published as a pre-print, suggests that semaglutide could be mass produced for $3 (about 2.35) for a monthly dose in its injectable form. Newer formulations, taken as a pill rather than an injection, could be made for about $16 a month.

In the mid-1990s, child mental health researchers at top New York institutions injected grade-school boys with fenfluramine, also known as the diet drug "fen-fen," a substance that was later banned by the Food and Drug Administration, due to its links to valvular heart disease and pulmonary hypertension. The boys were all Black or Hispanic by design: Eligible participants were required to be African American or Hispanic because they were deemed to be at higher risk for developing disruptive behaviors.